25.44USD+1.44%Mkt Cap: 3.22B USDP/E: —Last update: 2026-06-01
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor …
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap3.22B USD
Enterprise Value2.48B USD
Revenue (TTM)236.00M USD
Gross Profit-287.00M USD
Net Income (TTM)-353.00M USD
Revenue/Share2.067 USD
Last Price25.44 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees601
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.11
PEG—
EV/EBITDA-6.37
EV/Revenue10.50
P/S13.50
P/B6.07
EPS (TTM)-3.17
EPS (Forward)-3.12
52W Range
7.91084% of range28.72
52W High28.72 USD
52W Low7.910 USD
Profitability
Gross Margin-121.61%
Oper. Margin-788.24%
EBITDA Margin-164.83%
Profit Margin-142.91%
ROE-55.94%
ROA-30.99%
Growth
Revenue Growth-39.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-482.00M USD
CapEx (TTM)2.00M USD
FCF Margin-66.10%
FCF Yield-4.85%
Net Debt-709.00M USD
Net Debt/EBITDA1.82
Balance Sheet
Debt/Equity0.18
Current Ratio4.04
Quick Ratio3.97
Book Value/Sh4.175 USD
Cash/Share6.536 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Target (Mean)34.82 USD
Target Range22.00 USD – 47.00 USD
# Analysts11
Ownership
Shares Out.125.77M
Float89.09M
Insiders29.13%
Institutions72.47%
Short Interest
Short Ratio8.3d
Short % Float14.24%
Short % Out.8.66%
Shares Short10.89M
Short (prev mo.)11.07M
Technical
SMA 5023.63 (+7.7%)
SMA 20020.01 (+27.2%)
Beta0.87
S&P 52W Chg27.70%
Avg Vol (30d)1.14M
Avg Vol (10d)933.18K
Technical Indicators
RSI (14)55.0
MACD0.0309
MACD Signal0.0835
MACD Hist.-0.0527
BB Upper26.55 USD
BB Middle24.62 USD
BB Lower22.68 USD
BB Width15.73%
ATR (14)1.293 USD
Vol Ratio (20d)1.59x